Virus-like particle vaccines for poliovirus types 1, 2, and 3 with enhanced thermostability expressed in insect cells. Issue 17 (17th April 2019)

• Record Type: Journal Article
• Authors: Xu, Yuhua; Ma, Shuzhi; Huang, Yangbo; Chen, Fengying; Chen, Liyun; Ding, Dong; Zheng, Yanping; Li, Hua; Xiao, Jing; Feng, Jin; Peng, Tao
• Is Part Of: Vaccine. Volume 37:Issue 17(2019)
• Page Start: 2340
• Page End: 2347
• Publication Date: 2019-04-17
• Subjects: Poliovirus -- Vaccine -- Thermostability -- Virus-like particle -- BEVS -- Insect cell; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2019.03.031
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Thermostable PV-sVLPs were produced in large quantity. PV-sVLPs were characterized by electron microscopy. PV-sVLPs had significant D antigen content. PV-sVLPs could induce strong humoral and cellular immune responses in mice. Abstract: Poliovirus (PV) is a pathogen that causes poliomyelitis, which may lead to paralysis and fatality. Inactivated PV vaccines (IPVs) and live-attenuated oral PV vaccines (OPVs) are currently used to defend against PV worldwide. Vaccines must be developed in a PV-free environment given the biosafety issues associated with OPV and IPV production and to eradicate PV globally. In this study, PV1, PV2, and PV3 virus-like particles with enhanced thermostability (PV-sVLPs) were produced in large quantities by using a baculovirus expression vector system (BEVS). Mice immunized with PV-sVLPs generated antibodies with strong PV-neutralizing response. In addition, splenocytes collected from immunized mice expressed high levels of IFN-γ, IL-2, GM-CSF, IL-5, and IL-10 upon PV-sVLPs stimulation. These data suggest that PV-sVLPs can serve as vaccines against PV infection.